PMV Pharmaceuticals Inc Stock

$1.07

0.93% yesterday

Nasdaq, Jun 27, 10:00 pm CET

ISIN

US69353Y1038

Symbol

PMVP

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Services

Industry

Various services

Overview Dividends Analysts Charts News Strategies

PMV Pharmaceuticals Inc Stock price

$1.07

-16.93 94.06% 5Y

Nasdaq, Closing price Fri, Jun 27 2025

-0.01 0.93%

ISIN

US69353Y1038

Symbol

PMVP

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Services

Industry

Various services

Key metrics

Basic

Market capitalization

$55.6m

Enterprise Value

$-104.8m

Net debt

$-160.4m

Cash

$160.4m

Shares outstanding

52.0m

Valuation (TTM | estimate)

P/E

negative | negative

P/S

- | -

EV/Sales

- | -

EV/FCF

1.96

P/B

0.35

Financial Health

Equity Ratio

92.05%

Return on Equity

-33.34%

ROCE

-55.20%

ROIC

Debt/Equity

0.00

Financials (TTM | estimate)

Revenue

$0.0 | $0.0

EBITDA

$-88.0m | $-98.2m

EBIT

$-88.8m

Net Income

$-60.9m | $-81.8m

Free Cash Flow

$-53.4m

Growth (TTM | estimate)

Revenue

- | -

EBITDA

-16.64% | -16.54%

EBIT

-15.50%

Net Income

6.50% | -39.29%

Free Cash Flow

8.24%

Margin (TTM | estimate)

Gross

EBITDA

- | -

EBIT

Net

- | -

Free Cash Flow

EPS

$-1.18

FCF per Share

$-1.03

Short interest

1.98%

Employees

47.00

Rev per Employee

$0.00

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Get Started for Free Today

PMV Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

??

11 Analysts have issued a PMV Pharmaceuticals Inc forecast:

10x Buy

91%

More details on Analyst Estimates Including Price Targets

11 Analysts have issued a PMV Pharmaceuticals Inc forecast:

Buy

91%

Hold

Analyst Estimates with Stock Price Targets

Financial data from PMV Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	- -	- 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	26 26	14% 14% -
- Research and Development Expense	63 63	16% 16% -
EBITDA	-88 -88	17% 17% -
- Depreciation and Amortization	0.82 0.82	43% 43% -
EBIT (Operating Income) EBIT	-89 -89	16% 16% -
Net Profit	-61 -61	6% 6% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

PMV Pharmaceuticals Inc Stock News

Neutral

GlobeNewsWire

●

about one month ago

PMV Pharmaceuticals to Participate at Upcoming Investor Conferences

PRINCETON, N.J., May 23, 2025 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that David H. Mack, Ph.D., President and Chief Executive Officer and Deepika Jalota, Pharm. D., Chief Development Officer, will participate at the...

Neutral

GlobeNewsWire

●

4 months ago

PMV Pharmaceuticals Reports Full Year 2024 Financial Results and Corporate Highlights

Enrollment on track in Phase 2 pivotal portion of PYNNACLE clinical trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C and KRAS wild-type advanced solid tumors; more than 90% of sites activated across the U.S., Europe, U.K., and Asia-Pacific; interim analysis data expected mid-2025 Enrollment commenced in the MD Anderson Cancer Center investigator-initiated Phase 1b study ev...

Neutral

GlobeNewsWire

●

5 months ago

PMV Pharmaceuticals to Participate at Upcoming Investor Conferences

PRINCETON, N.J., Feb. 11, 2025 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that David H. Mack, Ph.D., President and Chief Executive Officer and Deepika Jalota, Pharm. D., Chief Development Officer, will participate at the following in...

Company Profile

PMV Pharmaceuticals, Inc. engages in the development of p53 targeted small molecule drugs for the treatment of cancer. It combines unique biological understanding with pharmaceutical development focus. The company was founded by Arnold J. Levine, David Henry Mac, and Thomas E. Shenk in 2013 and is headquartered in New Jersey, NY.

Head office	United States
CEO	David Mack
Employees	47
Founded	2013
Website	www.pmvpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now